Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Non-malignant442 active trials9 approved drugs183 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Clinical trials
2,079 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00668148 | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma | completed | Phase 2 | 113 | Eli Lilly and CompanyINDUSTRY | 7 | Jul 17, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01874665 | A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor(GIST) | completed | Phase 2 | 45 | Ariad PharmaceuticalsINDUSTRY | 1 | May 18, 2018 | clinicaltrials |
| NCT02066675 | Trabectedin First Line Therapy In Unfit Sarcoma Study(TR1US) | completed | Phase 2 | 24 | Italian Sarcoma GroupNETWORK | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00867113 | Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 91 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT00401388 | A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas | completed | Phase 2 | 72 | AEterna ZentarisINDUSTRY | 0 | Mar 7, 2018 | clinicaltrials |
| NCT01210222 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00455559 | Ph II Study of Perifosine Plus Gleevec for Patients With GIST | completed | Phase 2 | 40 | AEterna ZentarisINDUSTRY | 0 | Feb 22, 2018 | clinicaltrials |
| NCT02267083 | Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma | completed | Phase 2 | 22 | Gem PharmaceuticalsINDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02131662 | Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap(ASTEROID 1) | completed | Phase 2 | 309 | BayerINDUSTRY | 13 | Dec 8, 2017 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00055237 | Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01055314 | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma | completed | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 4 | Aug 29, 2017 | clinicaltrials |
| NCT01861951 | A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma(EPAZ) | completed | Phase 2 | 120 | Hannover Medical SchoolOTHER | 2 | Aug 21, 2017 | clinicaltrials |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | completed | Phase 2 | 291 | Children's Oncology GroupNETWORK | 5 | Jul 21, 2017 | clinicaltrials |
| NCT00332033 | Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids) | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00633295 | Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT01172548 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)(INV555) | completed | Phase 2 | 132 | Novartis PharmaceuticalsINDUSTRY | 12 | May 31, 2017 | clinicaltrials |
| NCT00356031 | Bevacizumab and Radiation Therapy for Sarcomas | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00045734 | Imatinib Mesylate in Treating Patients With Recurrent Meningioma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 15, 2017 | clinicaltrials |
| NCT01524848 | Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(PAGIST) | completed | Phase 2 | 72 | Scandinavian Sarcoma GroupOTHER | 5 | May 10, 2017 | clinicaltrials |
| NCT01222715 | Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 4 | May 5, 2017 | clinicaltrials |
| NCT01137916 | Study to Evaluate Imatinib in Desmoid Tumors | completed | Phase 2 | 39 | Heidelberg UniversityOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00413192 | E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 128 | Eisai Inc.INDUSTRY | 5 | Apr 26, 2017 | clinicaltrials |
| NCT01259375 | Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma(ARSARC-PI-0010) | completed | Phase 2 | 24 | University of UtahOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01185964 | A Study of Olaratumab in Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 148 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 14, 2017 | clinicaltrials |
| NCT00365872 | External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01110668 | Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00171912 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | completed | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00718562 | Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib | completed | Phase 2 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00031629 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT02465814 | Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids(ASTEROID 2) | completed | Phase 2 | 120 | BayerINDUSTRY | 16 | Nov 22, 2016 | clinicaltrials |
| NCT01483014 | Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)(CONVERT) | completed | Phase 2 | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00563680 | QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors | completed | Phase 2 | 38 | NantCell, Inc.INDUSTRY | 0 | Oct 27, 2016 | clinicaltrials |
| NCT01404650 | Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor | completed | Phase 2 | 25 | SCRI Development Innovations, LLCOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT02201420 | Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT | completed | Phase 2 | 5 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Sep 27, 2016 | clinicaltrials |
| NCT00287846 | Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis | completed | Phase 1 / Phase 2 | 40 | UNICANCEROTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT01067690 | Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma | completed | Phase 2 | 25 | Barbara Ensoli, MD, PhDOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT01283035 | A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01719302 | Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 6 | University of VermontOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT01347034 | Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS) | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT01478373 | Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib | completed | Phase 2 | 39 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 27, 2016 | clinicaltrials |
| NCT01039519 | A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 27 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Jul 17, 2018source: clinicaltrials